Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Kristina Lerch, Corinna Leng, Antonello Pinto, Werner Linkesch, Heinz Sill, Ola Linden, Andreas Viardot, Ulrich Keller, Georg Hess, MD, Secondo Lastoria, Ferdinando Frigeri, Nicole Neik, Christiane Pott, Christian W. Scholz, Antonio Pezzutto, MD PhD

Blood (2016) 128 (22): 1806.

https://doi.org/10.1182/blood.V128.22.1806.1806

Published: 2016

Journal Articles

Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.

Filippo Russo, MD, Gaetano Corazzelli, MD, Secondo Lastoria, MD, Gianpaolo Marcacci, MD, Ferdinando Frigeri, MD, Gaetana Capobianco, Cristina Becchimanzi, MD, Manuela Arcamone, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 715.

https://doi.org/10.1182/blood.V114.22.715.715

Published: 2009

Journal Articles

100% of Complete Response (CR) and Survival (FFP, OS) in Newly Diagnosed Patients with Advanced- and Intermediate-Stage Hodgkin’s Lymphoma (HL) Treated with Six Cycles of Dose-Dense, Dose-Intense (DD-DI) ABVD without Radiotherapy (RT).

Filippo Russo, MD, Gaetano Corazzelli, MD, Ferdinando Frigeri, MD, Secondo LaStoria, Antonio Pinto

Blood (2006) 108 (11): 2476.

https://doi.org/10.1182/blood.V108.11.2476.2476

Published: 2006

Journal Articles

The Impact of Relative Dose Intensity on Response and Survival in a Series of 180 Newly Diagnosed Patients with Hodgkin’s Lymphoma.

Filippo Russo, MD, Gino Svanera, MD, Paola Della Cioppa, MD, Gaetano Corazzelli, MD, Ferdinando Frigeri, MD, Gaetana Capobianco, MD, Secondo LaStoria, MD, Antonio Pinto, MD

Blood (2005) 106 (11): 2671.

https://doi.org/10.1182/blood.V106.11.2671.2671

Published: 2005

Journal Articles

Intensity of 18 Fluorodeoxyglucose Uptake in Positron Emission Tomography Is Associated with Unfavorable Prognostic Factors in Untreated Follicular Lymphoma.

Maria Luigia Vigliotti, MD, Giuseppe Cascini, MD, Ferdinando Frigeri, MD, Anna De Chiara, MD, Paola Della Cioppa, MD, Filomena Oliviero, MD, Secondo Lastoria, MD, Antonio Pinto, MD

Blood (2005) 106 (11): 1001.

https://doi.org/10.1182/blood.V106.11.1001.1001

Published: 2005

NARROW

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.

100% of Complete Response (CR) and Survival (FFP, OS) in Newly Diagnosed Patients with Advanced- and Intermediate-Stage Hodgkin’s Lymphoma (HL) Treated with Six Cycles of Dose-Dense, Dose-Intense (DD-DI) ABVD without Radiotherapy (RT).

The Impact of Relative Dose Intensity on Response and Survival in a Series of 180 Newly Diagnosed Patients with Hodgkin’s Lymphoma.

Intensity of 18 Fluorodeoxyglucose Uptake in Positron Emission Tomography Is Associated with Unfavorable Prognostic Factors in Untreated Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.

100% of Complete Response (CR) and Survival (FFP, OS) in Newly Diagnosed Patients with Advanced- and Intermediate-Stage Hodgkin’s Lymphoma (HL) Treated with Six Cycles of Dose-Dense, Dose-Intense (DD-DI) ABVD without Radiotherapy (RT).

The Impact of Relative Dose Intensity on Response and Survival in a Series of 180 Newly Diagnosed Patients with Hodgkin’s Lymphoma.

Intensity of 18 Fluorodeoxyglucose Uptake in Positron Emission Tomography Is Associated with Unfavorable Prognostic Factors in Untreated Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only